Dr. Licht’s distinguished career encompasses over two decades of pioneering research in the molecular mechanisms governing blood cancers. His work elucidating epigenetic dysregulation in leukemogenesis has opened new pathways for targeted therapies. Notably, his investigations revealed recurring mutations present in a substantial subset of relapsed B cell acute lymphoblastic leukemia (ALL) in pediatric patients and multiple myeloma cases. This discovery highlights the therapeutic potential of reversing aberrant epigenetic states as a disease-modifying strategy.

Licht’s academic trajectory began with a foundational medical education at Columbia University, followed by rigorous clinical training including a residency at Beth Israel Hospital and a fellowship in medical oncology at Dana-Farber Cancer Institute. His faculty appointments include notable tenures at Mount Sinai and Northwestern University, where he integrated clinical expertise with cutting-edge research initiatives. Most recently, at the University of Florida Health Cancer Institute, Licht’s leadership culminated in the center’s designation as a National Cancer Institute cancer center, underscoring his strategic vision and administrative acumen.

Van Andel Institute’s CEO and Chairman, David Van Andel, expressed enthusiasm about Licht’s appointment, citing his innovative approach to cancer biology and commitment to collaborative research frameworks. The institute aims to leverage Licht’s experience toward expanding interdisciplinary programs that interface epigenetics with neurodegeneration and metabolic diseases, areas increasingly recognized for their intertwined molecular underpinnings.

Beyond his scientific accomplishments, Licht’s editorial and organizational contributions have significantly shaped hematological oncology. He serves as the founding editor-in-chief of the journal Blood Neoplasia and has held editorial roles with Oncogene, Cancer Discovery, Cancer Cell, and Blood Cancer Discovery. His leadership extends to influential roles in professional societies such as the American Society of Hematology and the American Association for Cancer Research, contributing to the field’s evolving clinical and research frontiers.

The cornerstone of Licht’s laboratory research focuses on characterizing the epigenetic alterations that drive malignant transformation and progression in hematological cancers. By harnessing genomic and biochemical approaches, his team investigates the dynamic chromatin landscape governing gene expression programs critical for cancer cell survival and resistance mechanisms. This research enriches the understanding of how epigenetic therapeutics may be tailored to disrupt oncogenic circuits selectively.

Dr. Licht emphasizes the importance of translational science that bridges molecular discoveries with clinical application. His initiatives foster collaborative partnerships between academic institutions, healthcare centers, and industry stakeholders to accelerate the development of novel epigenetic inhibitors and combinational treatment regimens. Such efforts align with Van Andel Institute’s mission to translate foundational insights into tangible interventions benefitting patients worldwide.

In his forthcoming role, Licht intends to cultivate cross-disciplinary collaborations that amplify Van Andel Institute’s strengths in structural biology, cell biology, and biomedical informatics. By synergizing these domains, the institute is poised to deepen mechanistic insights and expedite biomarker discovery, thereby enhancing precision medicine strategies across a spectrum of diseases beyond hematology, including neurodegenerative disorders.

Peter A. Jones’s enduring impact as a pioneer in cancer epigenetics laid the groundwork for Van Andel Institute’s ascendancy as a global leader in biomedical innovation. His continued engagement as a faculty member ensures the institute remains tightly integrated with cutting-edge clinical trial networks, including the Van Andel Institute–Stand Up To Cancer Epigenetics Dream Team, which probes promising novel therapies in oncology.

Dr. Licht’s prolific scientific output—comprising over 240 peer-reviewed publications amassing more than 37,000 citations—reflects an impactful body of work that blends mechanistic insight with clinical relevance. His accolades, including the American Society of Hematology Basic Science Mentor Award and election as a fellow of the American Association for the Advancement of Science, affirm his role as both a visionary researcher and dedicated mentor.

As Van Andel Institute embarks on this new chapter under Licht’s stewardship, the convergence of expert leadership and a dynamic research environment promises to catalyze breakthroughs in understanding and treating complex diseases. The institute’s sustained commitment to integrating epigenetic science with innovative biomedical techniques positions it to drive transformative advances benefiting patients globally.

Situated at the nexus of a vibrant biomedical community in Grand Rapids, Van Andel Institute continues to expand its collaborative footprint across the Midwest. Licht’s strategic vision includes expanding partnerships with regional medical institutions and academic centers to foster an ecosystem that accelerates discovery, education, and clinical translation in an era of personalized medicine.

Ultimately, Jonathan D. Licht’s appointment heralds a future where Van Andel Institute’s pioneering science will increasingly unravel the epigenomic basis of cancer and other diseases, while training the next generation of biomedical scientists capable of navigating the complexities of human health and disease. His leadership signals a renewed commitment to scientific excellence, collaborative innovation, and impactful patient-centered research.

Subject of Research: Hematological malignancies, epigenetic regulation of blood cancers, cancer biology, translational medicine
Article Title: Van Andel Institute Appoints Dr. Jonathan D. Licht as New President and Chief Scientific Officer
News Publication Date: October 29, 2025
Web References: https://www.vai.org; https://joneslab.vai.org; https://www.vai.org/research/research-departments/epigenetics/
Image Credits: Courtesy of Van Andel Institute
Keywords: Health and medicine, Epigenetic regulation, Cancer

Down Syndrome, a genetic condition characterized by the presence of an extra copy of chromosome 21, predisposes individuals to a wide spectrum of health issues. Notably, individuals with DS experience a significantly elevated risk—approximately 10 to 20 times higher than the general population—of developing acute leukemia during childhood. Despite advances in treatment protocols and survival rates, the late effects of leukemia and its therapy on this vulnerable cohort have remained insufficiently explored.

The ALTE22C1 study adopts an innovative prospective and retrospective cohort design, enabling researchers to rigorously compare survivors of DS-associated acute leukemia against a control group of peers with DS but no history of cancer. Targeting survivors aged between 6 and 39 years who have been in remission for at least three years, this study bridges critical knowledge gaps by harnessing a blend of participant recruitment strategies from both registry data and site-based clinical settings.

Participants in the study undergo a thorough series of assessments encompassing medical conditions and neurocognitive functioning. These evaluations rely on a combination of parent-proxy reports and direct in-person assessments, encompassing detailed neuropsychological batteries and physical health examinations designed to pinpoint both overt and subtle sequelae of cancer therapy. Additionally, biological sample collection facilitates molecular analyses aimed at uncovering biomarkers and genetic factors that may underpin observed health outcomes.

What sets ALTE22C1 apart is its robust, multi-institutional collaborative framework. By pooling expertise and data across centers, the study promises unparalleled statistical power and generalizability. This approach facilitates the identification of patterns in chronic health conditions such as cardiopulmonary complications, endocrine dysfunctions, and neurodevelopmental impairments, which may disproportionately affect this population.

Existing studies on DS and leukemia have largely focused on survival metrics, with scant attention to the quality of life and long-term health trajectories after remission. The ALTE22C1 cohort study shifts the paradigm, emphasizing holistic survivor care. It explores how acute leukemia treatments intersect with the unique physiology and neurodevelopmental profile of individuals with DS, aiming to parse out treatment-related toxicity from the baseline vulnerabilities intrinsic to Down Syndrome.

One of the profound challenges addressed in this research is the differentiation between neurocognitive delays inherent to DS and additional impairments potentially exacerbated by leukemia treatment. By employing advanced neuropsychological batteries designed for sensitivity and specificity, the study meticulously delineates these overlapping conditions, providing invaluable data to optimize educational and supportive interventions.

Moreover, the molecular analyses incorporated in ALTE22C1 are expected to unravel pathophysiological mechanisms that may predispose DS-AL survivors to certain late effects. The investigation into genetic and epigenetic markers presents a pioneering avenue to personalize survivor care plans and initiate early interventions tailored to individual risk profiles.

The implications of this study extend beyond the clinical sphere, holding promise for informing evidence-based guidelines that can revolutionize follow-up care for DS-AL survivors. Currently, the scarcity of DS-specific survivorship recommendations leaves a significant void in clinical practice, often leading to under-recognition and inadequate management of chronic conditions in this group.

Through their diligent work, the Children’s Oncology Group researchers anticipate that ALTE22C1 will catalyze the development of targeted clinical protocols that directly address the unique needs of DS-AL survivors. These protocols may include enhanced surveillance regimens, neurodevelopmental support programs, and tailored rehabilitation strategies, all aimed at minimizing morbidity and enhancing life quality.

The AGTE22C1 study’s commitment to integrating patient and family perspectives via parent proxy reports underscores a patient-centered research ethos. Recognizing the crucial role of caregivers in interpreting and managing neurocognitive and physical health challenges, the study provides a more nuanced understanding of survivor experiences beyond clinical and laboratory metrics.

In contextualizing these findings within the broader landscape of pediatric oncology and genetic disorders, ALTE22C1 marks a seminal step forward. By juxtaposing DS-AL survivors against DS individuals without cancer and non-DS cancer survivors, the study elucidates the multifaceted influences shaping survivor outcomes, including genetic predisposition, treatment modalities, and psychosocial contexts.

The trial registration of ALTE22C1 under ClinicalTrials.gov identifier NCT05702645 affirms its methodological rigor and transparency, inviting the scientific community to engage with its progress and integrate emerging insights into practice. Its prospective/retrospective hybrid design optimizes the depth and breadth of data collection, enhancing the reliability and applicability of its findings.

Ultimately, this monumental endeavor is anticipated to propel the pediatric oncology field towards a more equitable and scientifically grounded approach in managing survivors of Down Syndrome-associated acute leukemia. By shining a spotlight on this vulnerable group, the study advocates for improved attention, resources, and tailored interventions that can transform survivorship care and outcomes.

As ALTE22C1 progresses, the oncology and genetics communities eagerly await its contributions, hopeful that its revelations will herald a new era of precision survivorship medicine catering to the complex needs of DS-AL survivors worldwide. The insights gleaned will not only refine clinical guidelines but also bolster advocacy efforts aimed at reducing the persistent health disparities faced by individuals living with Down Syndrome.

Subject of Research: Survivors of Down Syndrome-associated acute leukemia and their long-term medical and neurocognitive outcomes.

Article Title: A multicenter observational cohort study in survivors of Down Syndrome-associated acute leukemia (ALTE22C1): a report from the Children’s Oncology Group.

Article References:
Gramatges, M.M., Sanclemente, L.N., Hall, L. et al. A multicenter observational cohort study in survivors of Down Syndrome-associated acute leukemia (ALTE22C1): a report from the Children’s Oncology Group. BMC Cancer 25, 1611 (2025). https://doi.org/10.1186/s12885-025-14898-z

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14898-z